| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S19463 R82983 |
Straub (Controls exposed to LTG) (Phenytoin) (Epilepsy), 2026 | Autism spectrum disorder - ICD-10 codes: F84.x (except F84.2, F84.3) - Mean follow up (full cohort): 3.4 years | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
0.90 [0.47;1.71] C excluded (control group) |
13/1,390 34/3,273 | 47 | 1,390 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S19473 R83106 |
Straub (Controls unexposed, sick) (Phenytoin) (Epilepsy), 2026 | Autism spectrum disorder - ICD-10 codes: F84.x (except F84.2, F84.3) - Mean follow up (full cohort): 3.4 years | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes | 0.54 [0.29;0.98] | 13/1,390 106/8,887 | 119 | 1,390 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17393 R72922 |
Madley-Dowd_SE (Phenytoin) (Controls exposed to LTG), 2024 | Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
2.20 [0.98;4.92] C excluded (control group) |
7/147 53/2,383 | 60 | 147 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17394 R72926 |
Madley-Dowd_SE (Phenytoin) (Controls unexposed, sick), 2024 | Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 0.80 [0.38;1.70] | 7/147 425/10,769 | 432 | 147 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17253 R72210 |
Madley-Dowd_UK (Phenytoin) (Epilepsy), 2024 | Autism - ICD10 codes - Median follow up 10.75 (7.82-13.62) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes | 1.19 [0.17;8.52] | -/45 78/4,075 | - | 45 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6601 R18099 |
Bromley (Phenytoin) (Controls exposed to Lamotrigine, sick), 2008 | Autism spectrum disorder (a majority aged 6 and above) | early pregnancy | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
5.38 [0.30;95.06] C excluded (control group) |
1/9 1/44 | 2 | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6594 R18089 |
Bromley (Phenytoin) (Controls unexposed, disease free), 2008 | Autism spectrum disorder (a majority aged 6 and above) | early pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No |
13.88 [1.30;148.33] C excluded (control group) |
1/9 3/336 | 4 | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6598 R18094 |
Bromley (Phenytoin) (Controls unexposed, sick), 2008 | Autism spectrum disorder (a majority aged 6 and above) | early pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 18.60 [0.69;500.42] C | 1/9 0/47 | 1 | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 0.80 [0.39;1.62] | 552 | 1,591 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick) (Phenytoin) (Epilepsy; 2: Phenytoin) (Controls unexposed, sick; 3: Phenytoin) (Epilepsy; 4: Phenytoin) (Controls unexposed, sick;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 6601, 6594, 17393, 19463